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Abstract
The hydrophobic surfactant proteins, SP-B and SP-C, serve important roles in surfactant function and metabolism. Both
proteins are encoded by single genes, located on human chromosomes 2 and 8 respectively, which have been characterized
and extensively studied. Mutations in the SP-B gene have been shown to cause severe lung disease, and polymorphisms in the
SP-B gene may be associated with the development of RDS in premature infants. In contrast, mutations in the SP-C gene
have not yet been identified or shown to cause lung disease, although given the apparent importance of SP-C in surfactant
function, this remains a possibility. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Pulmonary surfactant is the mixture of lipids and
speci¢c proteins needed to reduce alveolar surface
tension and prevent end-expiratory collapse. An in-
ability to produce su⁄cient amounts of surfactant
due to pulmonary immaturity is the principal cause
of the respiratory distress syndrome observed in in-
fants born prematurely [1]. Pulmonary surfactant
contains at least four distinct speci¢c proteins which
have been identi¢ed to date. These include SP-A and
SP-D, which are larger, hydrophilic proteins, and
two smaller, extremely hydrophobic proteins, called
SP-B and SP-C. The hydrophobic proteins appear to
be critical for surfactant’s ability to lower surface
tension by enhancing adsorption and spreading of
surfactant phospholipid to the air-liquid interface
[2]. Both SP-B and SP-C are important components
of mammalian derived exogenous surfactant prepa-
rations used to treat infants with RDS such as Sur-
vanta1, Curosurf1, and Infasurf1. The importance
of SP-B in normal surfactant function is indicated by
the observations that infants or experimental animals
unable to produce SP-B develop lethal neonatal res-
piratory disease [3], and polymorphisms in the SP-B
gene were observed more frequently in infants with
RDS than in a control population [4]. Similar abnor-
malities in the SP-C gene have not yet been observed.
This review will focus on the contribution of varia-
tions in the SP-B and SP-C genes and their estab-
lished and potential roles in causing lung disease.
2. Surfactant protein B
SP-B is encoded on a single gene located on the
short arm on human chromosome 2, and has been
mapped by in situ hybridization to 2p12C2p11.2 [5].
The complete human, as well as murine, and rabbit
sequences, have been characterized [6]. It is a rela-
tively small gene, spanning approximately 9500
bases. It is comprised of 11 exons, of which the
11th exon is untranslated. The organization of the
murine and rabbit genes are similar in terms of the
number of exons, and relative size, although the
overall size of the gene is somewhat smaller in both
the mouse and rabbit due to the shorter size of sev-
eral introns. The production of SP-B is lung speci¢c,
and within the lung its expression is limited to non-
ciliated bronchiolar epithelial cells (Clara cells) and
alveolar type II cells. Although SP-B was the second
surfactant associated protein to be described, the
name of the SP-B locus is referred to as sftp3.
The 5P £anking region of the SP-B gene has been
extensively characterized, and contains sequences
that are important in conferring cell and tissue spe-
ci¢city of expression [7]. Proximal (nucleotides 380
to 3110) and more distal (3331 to 3439) cis-acting
elements that interact with the transcription factors
TTF-1 and members of the HNF-3 family have been
identi¢ed that appear to be particularly important
for SP-B expression [8,9]. Additional sequences in
this region with both non-speci¢c and cell speci¢c,
and positive and negative e¡ects on SP-B gene tran-
scription, have been identi¢ed [10].
The SP-B gene is transcribed into a 2000 base
mRNA, which directs the synthesis of a 381 amino
acid preproprotein. A 23 amino acid signal peptide,
encoded in the ¢rst exon, is removed co-translation-
ally. The resulting proprotein undergoes proteolysis
in at least two distinct steps to yield the mature
79 amino acid, 8700 Da protein found in the airspa-
ces [7]. Mature SP-B is encoded in exons 6 and 7 of
the SP-B gene. The ¢rst proteolytic processing step
removes the aminoterminal portion of the propro-
tein, whereas the second removes the carboxytermi-
nal portion (Fig. 1). These latter processing steps are
speci¢c to alveolar type II cells [11]. The enzymes
and the genes responsible for these processing steps
have not yet been identi¢ed. The protein sequences
of mature porcine and bovine SP-B have been di-
rectly determined [12,13], along with deduced amino
acid sequences determined from cDNA sequences
from a number of species [6,14], and are highly con-
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served with s 80% homology. The structure and
properties of SP-B are reviewed elsewhere in this
issue by Dr. S. Hawgood.
3. Hereditary SP-B de¢ciency
3.1. History and clinical aspects
Infants who are unable to produce SP-B develop
fatal lung disease, demonstrating the importance of
SP-B in normal lung function. The disease was ¢rst
recognized in 1993 in a family in which three full-
term infants died from lung disease of neonatal on-
set. Both parents and three siblings were free of pul-
monary symptoms suggesting an autosomal recessive
pattern of inheritance [3]. In all three a¡ected infants,
SP-B protein was undetectable in lung tissue by im-
munologic methods, while SP-A and the precursor
protein of SP-C were present in amounts comparable
to those in control tissues. SP-B mRNA was also
undetectable by Northern blot analysis, supporting
the hypothesis that the primary cause of disease
was an inability to produce SP-B. SP-B de¢ciency
was established as the cause of disease when the af-
fected infants were shown to be homozygous for a
frameshift mutation in exon 4 of the SP-B gene that
accounted for the lack of SP-B protein [15].
Since the initial description of the disorder, more
than 35 families with infants a¡ected by hereditary
SP-B de¢ciency have been identi¢ed (L. Nogee, un-
published observation). A¡ected infants have gener-
ally been born at or near term, and developed severe
respiratory symptoms shortly after birth. The pre-
senting clinical signs and symptoms are those of sur-
factant de¢ciency, including tachypnea, grunting,
£aring, retractions and need for supplemental oxy-
gen. Pulmonary hypertension is a frequent compo-
nent of the clinical picture, and it is not uncommon
for SP-B de¢cient infants to be treated with extra-
corporeal life support when available. The radio-
graphic appearance most often resembles that of
RDS in premature infants, although some a¡ected
infants have not had prominent in¢ltrates on chest
radiographs early on in the course of the illness, and
some have had more of an interstitial rather than
alveolar pattern. The clinical diagnosis most often
ascribed to such infants has been RDS, although
a¡ected infants have been thought to have persistent
pulmonary hypertension, presumed sepsis with neg-
Fig. 1. SP-B gene, mRNA, proprotein and processing. Exons and translated portions of the mRNA are represented by boxes; introns
and untranslated portions are represented by lines. The location of the 121ins2 mutation, an exon 4 coding polymorphism, and the in-
tron 4 CA repeat polymorphism are shown. Amino acids encoded by the exon 4 polymorphism, and the start and end of mature
SP-B are indicated by their single letter abbreviation.
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ative blood cultures, meconium aspiration syndrome,
and transient tachypnea of the newborn. The hy-
poxic respiratory failure in SP-B de¢cient infants is
severe and progressive, and almost all a¡ected in-
fants have been treated with mechanical ventilation,
and often with high frequency ventilation. A¡ected
infants may transiently improve following treatment
with exogenous surfactant preparations containing
SP-B, but the response is not sustained. Repeated
doses (almost 80) were ine¡ective in preventing
respiratory failure and death in an antenatally
diagnosed infant in whom surfactant replacement
therapy was initiated at birth [16]. Variable im-
provement has been seen in some children with
corticosteroid therapy [17]. The disease is ultimately
fatal, although with aggressive supportive therapy
SP-B de¢cient infants may survive for many months.
The costs of caring for these children are high, both
in economic terms and for the stresses imposed on
the family.
3.2. Pathology and pathophysiology
The lung pathology of SP-B de¢cient infants is
variable. The predominant ¢ndings are often non-
speci¢c changes due to lung injury, including alveo-
lar cell hyperplasia and interstitial ¢brosis [3,18]. One
particularly striking ¢nding on histopathologic ex-
amination of the lung tissue of many SP-B de¢cient
infants is the accumulation of granular, eosinophilic
material that stains positively with periodic acid-
Schi¡ reagent ¢lling distal air spaces. Foamy macro-
phages and desquamated alveolar cells are also ob-
served trapped in the alveolar material. This appear-
ance has been referred to as alveolar proteinosis,
because of the similarity in appearance to that of
adults and older children with this disorder. The na-
ture of the proteinosis material is di¡erent, in that it
lacks SP-B, whereas the alveolar proteinosis material
in older children or adults contains abundant SP-B,
as well as SP-A, SP-C, and surfactant phospholipid.
The amount of proteinaceous material observed is
variable and may be minimal in some cases. It is
unknown whether the variability in the amount of
proteinaceous material is related to e¡ects of treat-
ment, such as mode of ventilation or surfactant ther-
apy, duration of survival, or natural biologic varia-
bility of the disease. Additionally, mechanisms other
than SP-B de¢ciency can result in the histopatholog-
ical picture of alveolar proteinosis. Mice in whom
the genes for granulocyte macrophage colony stimu-
lating factor (GM-CSF) or its receptor were inacti-
vated developed these histopathologic ¢ndings
[19,20], and a de¢ciency of a component of the
GM-CSF receptor has recently been implicated in
the pathogenesis of alveolar proteinosis in human
infants [21], indicating that other genetic mechanisms
can produce similar pathology. Thus the term ‘he-
reditary SP-B de¢ciency’ more accurately describes
infants genetically unable to produce SP-B, rather
than the term ‘congenital alveolar proteinosis’, which
may result from mechanisms other than SP-B de¢-
ciency.
The incidence of SP-B de¢ciency is unknown,
although the disease appears to be quite rare. A dis-
proportionate number of families have had more
than one child a¡ected with this recessive disorder,
suggesting that in the absence of a family history of
neonatal respiratory disease cases have gone unrec-
ognized. The extent of phenotypic variation is also
unknown. The report of an infant with unexplained
chronic lung disease associated with reduced produc-
tion of SP-B supports the notion that milder forms
of the disease may be observed [17].
Experimental animals in whom antibodies directed
against mature SP-B were instilled intratracheally de-
veloped severe lung disease, supporting the role of
the mature peptide in normal lung function [22,23].
However, the pathophysiology of SP-B de¢ciency ap-
pears to be more complicated than simply related to
the lack of the mature protein. Unexpectedly, a num-
ber of secondary alterations in the content and me-
tabolism of other surfactant components have been
observed in SP-B de¢cient infants, suggesting addi-
tional roles for SP-B or its precursor protein in sur-
factant metabolism.
The lung tissue of all SP-B de¢cient infants studied
to date contains abundant 6000 to 12 000 Da pepti-
des that are strongly immunoreactive with antisera
directed against the SP-C proprotein. These peptides
are secreted into the lung £uid, and result in intense
immunohistochemical staining of the proteinaceous
material with anti-proSP-C antisera. Using antisera
directed against di¡erent epitopes of the SP-C pro-
protein, Vorbroker et al. concluded that these pep-
tides contain the aminoterminal portion of the
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proSP-C molecule, and likely result from incomplete
processing of the proprotein [24].
The mechanism whereby the lack of SP-B inter-
feres with SP-C processing remain unknown. Possi-
ble mechanisms could include a direct role for SP-B,
or proSP-B or one of its domains in the proteolysis
of proSP-C. Another possibility may relate to other
secondary abnormalities within the type II cell. Ul-
trastructural analysis of the lung tissue of SP-B de¢-
cient infants revealed reduced numbers of and poorly
formed lamellar bodies, the intracellular storage or-
ganelles of surfactant [25]. As the ¢nal processing
steps of SP-C take place in a distal cellular compart-
ment (multivesicular bodies or lamellar bodies), the
lack of the processing organelle could lead to disrup-
tion of SP-C processing.
Abnormalities in surfactant phospholipids have
also been observed in SP-B de¢cient infants. Amni-
otic £uid analyses from two a¡ected infants demon-
strated very abnormal phospholipid pro¢les at term,
with lecithin:sphingomyelin ratios of 6 1.0 (normal
s 2.0 at 38 weeks gestation), and an absence of phos-
phatidylglycerol [16,26]. Phosphatidylglycerol was
also markedly reduced in the lung £uid and tissue
of infants who underwent lung transplantation [26].
SP-A metabolism may also be altered in the absence
of SP-B. While the total amount of SP-A in lung
£uid and tissue did not di¡er markedly from that
of controls, immunohistochemical staining for SP-A
in lung tissue of de¢cient infants demonstrated in-
tense staining of the extracellular proteinaceous ma-
terial, however epithelial cell staining for SP-A stain-
ing was sparse compared that of control lung tissues
[18]. The functional signi¢cance of alterations in SP-
A metabolism remains unknown.
The proteinaceous material that accumulates in the
airspaces of SP-B de¢cient infants thus contains
abundant amounts of SP-A and aberrant SP-C,
and a relative paucity of surfactant phospholipid.
Mature SP-C protein was not detected in lung or
amniotic £uid from SP-B de¢cient infants [24].
Thus the respiratory failure in SP-B de¢cient infants
may result not only from the lack of SP-B, but pos-
sibly from the lack of SP-C, the accumulation of
non-surface active proteins, and derangement of
type II cell intracellular metabolism. The mechanisms
underlying these secondary changes in surfactant me-
tabolism remain to be elucidated. One hypothesis is
that SP-B, or other domains of proSP-B, may be
necessary for the proper formation of lamellar
bodies. In the absence of the proper development
of this intracellular organelle, surfactant phospholi-
pid and proteins cannot be packaged properly. Clar-
i¢cation of the mechanisms involved in derangement
of surfactant metabolism in SP-B de¢ciency should
provide insights into type II cell function.
3.3. Genetics of SP-B de¢ciency
The common mutation responsible for SP-B de¢-
ciency involves a substitution of GAA for C in co-
don 121, a net 2 base pair insertion that causes a
frameshift, and premature signal for the termination
of translation, accounting for the lack of SP-B pro-
tein [15]. This mutation, termed 121ins2, has ac-
counted for approximately 2/3 of the mutant alleles
identi¢ed to date. It has been found principally in
families of Northern European, Anglo-Saxon, and
Scottish-Irish descent. However a¡ected infants
have been identi¢ed in other ethnic groups, including
families of Middle Eastern, Mediterrean, and Asian
descent. It is not known whether the common muta-
tion resulted from a founder e¡ect, or due to a mech-
anism causing a recurrent de novo mutation at the
same site. While the exact population frequency of
the 121ins2 mutation is also unknown, it appears to
be low. Thus identi¢cation of this mutation in pa-
tients with clinical features of SP-B de¢ciency can be
useful diagnostically [26]. Two other mutations have
been described, both of which result in only a single
amino acid change, and allow for production of
proSP-B [17,27]. Clinical disease associated with pro-
duction of abnormal SP-B peptides is possible. Other
mechanisms that could result in SP-B de¢ciency,
which have not yet been observed, include deletions
or rearrangements of the SP-B gene, mutations in
sequences important for SP-B gene regulation, or
mutations in other genes encoding proteins needed
for SP-B gene transcription. As proSP-B undergoes
proteolytic processing to yield the mature peptide,
mutations in the gene needed for SP-B processing
could also potentially result in disease.
3.4. Treatment
Treatment options for SP-B de¢cient infants re-
BBADIS 61782 2-11-98
L.M. Nogee / Biochimica et Biophysica Acta 1408 (1998) 323^333 327
main limited. The disease is invariably fatal, and
currently the only available treatment options for
SP-B de¢cient infants are provision of compassionate
care for the infant and family, or lung transplanta-
tion. Experience with lung transplantation for SP-B
de¢ciency has been reported in three infants [26].
One infant died of adenoviral infection shortly after
the procedure, however two others have had encour-
aging short-term results. Experience with lung trans-
plantation in infants is limited however, and the
long-term outlook for these children is unknown. It
is unlikely that protein replacement with the mature
peptide would be su⁄cient to adequately treat the
disease. SP-B replacement by administration of mul-
tiple (s 80) doses of exogenous surfactants contain-
ing bovine SP-B was attempted in an antenatally
diagnosed SP-B de¢cient infant beginning at birth
[13]. While this child’s initial lung disease was less
severe than that of a previous sibling, his lung dis-
ease still progressed and he died awaiting lung trans-
plantation. Post-mortem analysis of the lung tissue
did not exhibit alveolar staining for SP-B suggesting
that the exogenously administered SP-B was not in-
corporated intracellularly. Multinucleated giant cells
within granulomata that stained positively for SP-B
were observed in lung tissue, suggesting that the exo-
genously administered SP-B was not metabolized
normally. Additionally, the defect in SP-C processing
was not corrected. It is possible that the amounts of
SP-B used to treat this infant were insu⁄cient, or
that there was toxicity due to the other surfactant
components administered. Puri¢ed preparations of
SP-B for aerosolization or intratracheal administra-
tion are not available. It is likely however that intra-
cellular synthesis of SP-B will be necessary to correct
the metabolic alterations in surfactant processing
within the type II cell. This consideration, along
with the tissue speci¢city of SP-B expression, the
rapidly fatal nature of the disease, and lack of treat-
ment alternatives, make SP-B de¢ciency an impor-
tant disease model for gene therapy in the lung. Pre-
liminary experience with viral vectors capable of
directing SP-B synthesis in tissue culture and exper-
imental animals has been reported, but considerably
more work needs to be done before they are ready
for clinical use [28^30].
3.5. Animal models of SP-B de¢ciency
Clark and colleagues developed SP-B ‘knock-out’
mice by targeted disruption of the SP-B gene [31].
Homozygous SP-B de¢cient mice lacked SP-B specif-
ic mRNA and protein, and did not expand their
lungs and died within minutes of birth. This mouse
model resembles the human disease in that SP-C is
also not processed appropriately, and lamellar body
formation is disrupted. These animals provide an in-
valuable tool for studying the pathophysiology of the
disease, and for studying potential therapeutic op-
tions. Akinbi and colleagues generated a transgenic
mouse line who carried an SP-B gene construct
which encoded the aminoterminal portion and ma-
ture SP-B peptide, but lacked the carboxyterminal
portion of proSP-B, under the control of the SP-C
promoter [32]. These mice expressed SP-B from the
transgene, and were crossbred with mice heterozy-
gous for the disrupted SP-B allele to eventually ob-
tain mice that expressed SP-B only from transgene in
the null background. These animals survived, indi-
cating that they could be rescued by reconstituting
SP-B expression. Additionally, these experiments in-
dicate that the carboxyterminal portion of proSP-B
is not essential for survival.
4. SP-B gene polymorphisms and respiratory distress
syndrome
In addition to the mutations in the SP-B gene as-
sociated with acute respiratory failure in full-term
infants, a number of polymorphisms have been iden-
ti¢ed in the SP-B gene. One coding polymorphism at
the end of exon 4 has been recognized, although not
commented on, in previous reports [6]. One allele
encodes isoleucine at codon 131, the other threonine.
The substitution of isoleucine for threonine would
abolish a consensus signal for N-linked glycosylation
at this site. It is unlikely that glycosylation at this
location is essential, as this glycosylation site is not
present in other mammalian species [14]. The distri-
bution of these two alleles in the population is not
known, nor whether either allele could predispose to
or possibly be associated with disease.
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A highly polymorphic region containing a variable
nucleotide tandem repeat (VNTR) sequence is lo-
cated within intron 4 of the SP-B gene. The variation
in the size of these repeats accounts for a previously
recognized SP-B restriction fragment length poly-
morphism (RFLP) for BamH1 [5]. The di¡erent al-
leles due to variations in this region have been ex-
tensively characterized by Floros and coworkers [4].
At least 12 di¡erent alleles have been identi¢ed, each
containing a variable number (from 3 to 18) of mo-
tifs consisting of a conserved 20 bp element followed
by a variable length of (CA)n repeats. Di¡erences in
the distribution of alleles in di¡erent ethnic groups
were observed. The most common allele contains 11
motifs, and accounted for 90% of the alleles in Cau-
casian individuals, but for a lesser percentage in Afri-
can-Americans (75%) and Nigerian (83%) individu-
als. The second most common allele (5%) in the
Caucasian group had ¢ve motifs deleted, whereas
insertions of motifs were more common in the Afri-
can-American and Nigerian groups [33].
The functional signi¢cance of these small intronic
insertions and deletions is unknown. Floros et al.
examined the association of SP-B alleles that di¡ered
at this locus with the development of RDS in pre-
mature infants. They found that 32% of infants with
RDS had a polymorphism (either insertion or dele-
tion of extra motifs as opposed to the most com-
monly observed allele), whereas only 9.5% of the
control group had a polymorphism [4]. However,
the RDS infants were signi¢cantly more premature
in terms of their gestational age, a known risk factor
for RDS, so that the association could also be re-
lated to prematurity. In a subsequent study, the fre-
quency of an SP-B polymorphism at this locus in
combination with an SP-A gene polymorphism, was
signi¢cantly higher in babies with RDS than in a
control group comparable for gestational age and
ethnic background [34].
The mechanism(s) whereby these polymorphisms
could be associated with disease remain unclear, as
this type of polymorphic variation is not one that
would obviously a¡ect SP-B regulation. It is possible
that the polymorphic markers could be linked to
abnormalities elsewhere in the gene a¡ecting SP-B
production or processing, although the association
was with having any polymorphism, and not a par-
ticular allele. Individuals who are carriers for SP-B
de¢ciency, and who have one allele incapable of pro-
ducing SP-B, have in general not had histories of
pulmonary disease, although systematic studies ex-
amining pulmonary function in such individuals
have not been performed. Interestingly, mice hetero-
zygous for one abnormal SP-B allele developed air
trapping as adults [35], suggesting that having one
abnormal SP-B allele may be a risk factor for the
development of lung disease. Finally, the recent re-
port of an infant with a mutation on one allele re-
sulting in a single amino acid substitution, and one
apparently normal allele, who initially had undetect-
able SP-B levels in his lung £uid, but whose SP-B
levels increased as his lung disease improved [27],
also supports the notion that one abnormal allele
could be associated with lung disease in some cir-
cumstances.
5. Surfactant protein C
Human SP-C is encoded by a single gene located
on the short arm of chromosome 8, centromeric to
8p23.1, and the locus is referred to as sftp2 [36]. It is
a fairly small gene, spanning only 3500 bases. The
gene contains six exons and ¢ve introns; the last
exon is untranslated [37]. The SP-C gene is located
in close proximity to the gene for bone morphoge-
netic protein-1 (BMP-1), whose transcription initia-
tion site is located only 706 bases downstream of the
polyadenylation site of the SP-C gene [38]. The gene
is transcribed into a 0.86 kb mRNA, which directs
the synthesis of a 22 000 Da proprotein. Alternative
splicing at the beginning of exon 5 leads to two
di¡erent transcripts, which di¡er by 18 bases in
length [37]. The resulting proproteins thus di¡er by
six amino acids. The functional signi¢cance of this
alternative splicing is unknown. The proprotein is
further proteolytically processed to yield the ex-
tremely hydrophobic 35 amino acid SP-C protein
found in the airspaces (Fig. 2). The DNA sequence
from which the mature SP-C peptide is derived is
located in exon 2. Two cysteine residues contained
in the mature SP-C peptide are posttranslation-
ally palmitoylated, and SP-C is thus a proteolipid
[39]. The enzymes involved in the posttranslational
processing of proSP-C to mature SP-C have not
been characterized. The structure and properties of
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SP-C are reviewed by Johansson elsewhere in this
issue.
The SP-C gene promoter contains sequences di-
recting lung speci¢city and cell speci¢city to the dis-
tal respiratory epithelium, and SP-C expression is
restricted to alveolar type II cells in human lung. A
3.7 kb portion of the sequence 5P to the SP-C gene
has been used extensively to target a number of
transgenes to the distal respiratory epithelium in
mice [40].
The initial characterization of the SP-C gene re-
vealed two groups of clones which di¡ered consider-
ably in their DNA sequences at multiple locations,
including single nucleotide substitutions, insertions,
and deletions, primarily in intronic sequences [37].
Southern blot analysis however, was consistent with
a single SP-C gene [36], and the observed sequence
di¡erences were thus likely due to di¡erent SP-C
alleles. Variations in SP-C cDNA sequences had
been observed previously, including coding sequence
changes at codons 138 (Asn or Thr) and codon 186
(Asn or Ser) [41]. It is not known whether these
variants have any correlation with disease. While
the SP-C gene sequences that have been reported to
date di¡er considerably from one another, the extent
of allelic variation and distribution of di¡erent SP-C
alleles in the general population remain unknown. A
single base deletion in intron 5 creates an EcoR1
RFLP, and a highly polymorphic (CA)n repeat re-
gion is located in close proximity to the SP-C gene
(within the ¢rst intron of the BMP-1 gene) [38].
These polymorphic markers may be useful in studies
attempting to link the SP-C gene with disease.
To date, variations in the SP-C gene have not been
associated with human disease. Hatzis et al. exam-
ined SP-C mRNA expression as assessed by in situ
hybridization in eight infants who died from RDS
and ten control infants who died from other causes
[42]. They found similar levels of SP-C mRNA ex-
pression in both groups, and concluded that altered
SP-C expression due to pretranslational mechanisms
was unlikely to contribute to the pathogenesis of
RDS. They also found that the SP-C gene sequences
from four healthy adults without lung disease of dif-
ferent ethnic backgrounds (two Caucasian, two Ni-
gerian), and from two premature Caucasian infants
with RDS, did not di¡er from one another, although
di¡erences from previously reported sequences were
Fig. 2. SP-C gene, mRNA, proprotein and processing. Exons and translated portions of the mRNA are represented by boxes; introns
and untranslated portions are represented by lines. The positions of a coding polymorphism in exon 5 and an EcoR1 RFLP are
shown. Amino acids corresponding to the beginning and end of mature SP-C and the polymorphism are indicated by their single let-
ter abbreviation. The proposed block that occurs in SP-C processing in the absence of SP-B is indicated by a dashed line.
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observed. SP-C protein expression was not examined
in this study. In contrast, in a recent preliminary
report, Wert et al. observed markedly decreased
staining for proSP-C in the lungs of 15 full-term
infants who died from respiratory distress syndrome
[43]. In three instances, more than one infant born to
the same parents was a¡ected, suggesting a genetic
basis for their disease, although no SP-C gene muta-
tions were identi¢ed in this study. These observations
support a role for SP-C or proSP-C in the patho-
genesis of some infants with neonatal respiratory
failure.
It is not known whether speci¢c mutations in the
SP-C gene result in respiratory disease. Such muta-
tions have not yet been reported, nor has targeted
disruption of the SP-C gene in experimental animals
been reported. However, given the small size of the
SP-C gene, such mutations may be quite rare. It is
possible that SP-C’s role in surfactant and/or type II
cell function may not be essential, with SP-B or other
proteins able to compensate for a lack of SP-C, and
that mutations in the SP-C gene will not cause res-
piratory disease. Alternatively, it may be that SP-C
gene mutations could be lethal prenatally rather than
causing lung disease postnatally, although this would
be surprising given the restriction of SP-C expression
to the distal respiratory epithelium.
6. Future directions
Much remains to be learned concerning the role of
mutations and polymorphisms in the SB-B and SP-C
genes and their contribution to human lung disease.
The recognition of hereditary SP-B de¢ciency as a
cause of lung disease has raised additional questions.
The incidence of the disease remains to be deter-
mined. The mechanisms whereby the lack of SP-B
disrupts other aspects of surfactant metabolism
need to be elucidated. Better treatment options
need to be developed, and the disease is an important
model for gene therapy in the lung. Finally the con-
tribution of more subtle mutations and polymor-
phisms in the SP-B (and possibly SP-C) gene(s) to
the development of other lung diseases (such as
chronic lung disease and recovery from lung injury)
deserves more investigation.
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